PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for

PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for

Testicular germ cell tumors (TGCTs), the most common malignancies affecting young men, are characterized by high sensitivity to cisplatin-based chemotherapy, which leads to high cure rates even in metastatic disease. However, approximately 30% of patients with metastatic TGCTs relapse after first-li...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Parola, Christoph Oing, Pasquale Rescigno, Salvatore Feliciano, Francesca Carlino, Luca Pompella, Antonella Lucia Marretta, Irene De Santo, Martina Viggiani, Margherita Muratore, Bianca Arianna Facchini, Jessica Orefice, Eleonora Cioli, Francesca Sparano, Domenico Mallardo, Ugo De Giorgi, Giovannella Palmieri, Paolo Antonio Ascierto, Margaret Ottaviano
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Genetics
Subjects:
testicular tumors
germ cell tumors
cisplatin resistance
PARP inhibitors
DNA damage response
homologous recombination repair
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2024.1480417/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2024.1480417/full

Similar Items